Leerink analyst Geoffrey Porges says that the recent positive SOLO Phase 3 results increased his confidence, probability of success and forecast for Regeneron (REGN)/Sanofi (SNY) dupilumab's long term potential. Further, the analyst notes that the results of a large survey of dermatologists about the Phase 3 results and how they plan to use dupilumab surprised him with their enthusiasm for the data, the medication, and their intended prescribing. While surveys can be misleading, if the survey results translated into real world adoption they suggest it could surprise to the upside. He reiterates an Outperform rating and $513 price target on Regeneron's shares.

After IGM Biosciences (IGMS) announced that the company's exclusive worldwide collaboration agreement with Sanofi (SNY) to create and develop IgM agonist antibodies will now focus exclusively on immunology and inflammation targets, Stifel analyst Stephen Willey said the firm believes the re-focusing of the collaboration away from oncology and exclusively to the three, yet-to-be-disclosed IAI targets "removes some longer-term economic optionality," but ultimately doesn't change the firm's thesis on the stock. The firm, which adds that Sanofi's decision aligns with its continued prioritization of IAI development opportunities and doesn't reflect anything aplitabart-related and notes that IGM now regains full control of these oncology programs and could potentially re-monetize these assets via future partnerships, would be buyers on related weakness. Stifel has a Buy rating and $25 price target on IGM Biosciences shares.